Join
Live feed
·
PRReleasevia Quantisnow
Agenus Inc. logo

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

ByQuantisnow·Wall Street's wire, on your screen.
AGEN· Agenus Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGEN (Agenus Inc.) and more on Quantisnow.